Supplementary Figure 1



Supplementary Figure 1. A representative gating strategy for the DC assay. A total of 150000 cellular events were acquired from 0.1 mL of whole blood. (A) Apoptotic cells and duplicates were excluded based on forward scatter and side scatter characteristics. (B) The first gate was set on the lymphocyte and monocyte area. (C) The second gate was set on lineage- and HLA-DR+ cells. (D) The pDCs were identified as Lineage-HLA-DR+CD123+CD11c- (Q3); the cDC2-like cells were identified as Lineage-HLA-DR+CD123+CD11c+ (Q2); the pre-cDCs were identified as Lineage-HLA-DR+CD123-CD11c+ (Q1).

Supplementary Figure 2



Supplementary Figure 2. Phenotype of three DC subsets in the circulation of patients with COVID-19**. (a)** $CD123^{+}CD11c^{+}$ cDC2-like cells expressed significantly higher levels of CD11c compared to $CD123^{-}CD11c^{+}$ pre-cDCs. **(b)** $CD123^{+}CD11c^{+}$ cDC2-like cells expressed similar levels of CD123 compared to $CD123^{+}CD11c^{-}$ pDCs. **(c)** $CD123^{+}CD11c^{+}$ cDC2-like cells expressed significantly higher levels of CD11c compared to CD123. **(d)** $CD123^{+}CD11c^{-}$ pDCs and $CD123^{+}CD11c^{+}$ cDC2-like cells expressed significantly higher levels of HLA-DR compared to pre-cDCs. Abbreviations: HLA-DR, Human leukocyte antigen-DR isotype; pDCs, plasmacytoid dendritic cells; cDCs, conventional dendritic cells; MFI, median fluorescence intensity.